| __timestamp | Alpine Immune Sciences, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 2287709 | 5114000 |
| Thursday, January 1, 2015 | 6844000 | 13403000 |
| Friday, January 1, 2016 | 8586000 | 31056000 |
| Sunday, January 1, 2017 | 6079000 | 35845000 |
| Monday, January 1, 2018 | 8362000 | 48294000 |
| Tuesday, January 1, 2019 | 9467000 | 63488000 |
| Wednesday, January 1, 2020 | 10899000 | 88208000 |
| Friday, January 1, 2021 | 14560000 | 102802000 |
| Saturday, January 1, 2022 | 17968000 | 102464000 |
| Sunday, January 1, 2023 | 22222000 | 76162000 |
| Monday, January 1, 2024 | 72977000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Alpine Immune Sciences, Inc. and CRISPR Therapeutics AG, two pioneers in the field, have shown contrasting approaches over the past decade.
From 2014 to 2023, CRISPR Therapeutics AG consistently reported higher SG&A expenses, peaking at approximately $102 million in 2021. This reflects their aggressive expansion and investment in cutting-edge gene-editing technologies. In contrast, Alpine Immune Sciences, Inc. maintained a more conservative approach, with expenses growing from $2.3 million in 2014 to $22 million in 2023, a tenfold increase.
While CRISPR's strategy may indicate a robust market presence, Alpine's careful cost management could suggest a focus on sustainable growth. As the biotech landscape evolves, these strategies will play a pivotal role in shaping their future trajectories.
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Who Optimizes SG&A Costs Better? Sanofi or Alpine Immune Sciences, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Jazz Pharmaceuticals plc vs Alpine Immune Sciences, Inc.
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Alkermes plc and CRISPR Therapeutics AG: SG&A Spending Patterns Compared
Opthea Limited vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Alpine Immune Sciences, Inc. and Veracyte, Inc.
Alpine Immune Sciences, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and Novavax, Inc.
Comparing SG&A Expenses: Alpine Immune Sciences, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc.